14th Asia-Pacific Breast Cancer Summit 2026 shared a post on LinkedIn:
“Risk stratification in HR-positive, HER2-negative early breast cancer (eBC) is rapidly evolving. As our understanding of disease biology deepens, clinicians are increasingly challenged to move beyond traditional risk models to support more precise, individualized treatment decisions.
This Breakthrough Symposium at APBCS 2026 will examine emerging evidence, novel approaches, and future directions that are reshaping how risk is defined—and how it informs therapeutic strategies in early-stage disease.
Talk: Redefining Risk in HR+ HER2- eBC
Date: Saturday, 7 February 2026
Time: 11:15 – 11:45 (Malaysia Time)
Venue: St Giles Wembley Penang, Malaysia
Designed for medical oncologists, breast surgeons, and multidisciplinary care teams, this session offers forward-looking insights to support evidence-based, patient-centred care.
More posts about APBCS26.